In the blockbuster movie. The Devil’s Advocate, Al Pacino’s character, John Milton, said: “Vanity, definitely my favorite sin.” One penny stock, Fibrocell Science, Inc. (FCSC), is looking to capitalize big on Vanity after closing a $45 million private placement last week to expand production. The Company’s LAVIV is the first and only FDA-approved treatment that uses your own collagen-producing cells to improve the look of your smile lines. With The Wall Street Journal recognizing LAVIV as part of its Technology Innovation Awards earlier this month, FCSC stock notched its highest volume trading session Friday since April.
With plans to reverse split for listing on a higher exchange, FCSC is a good penny stock to have a long position in.
Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
FCSC Stock Chart
Market Cap: 19.34M
Close: 0.195, up 0.005 (2.63%)
Dollar Volume: $487,421
Average Trade Size: 128,290
Issued and Outstanding: 658,610,200
Looking for Hot Penny Stocks?
Click here and get Alerts on the Best Penny Stocks FREE
Preparing for the closing of the Securities Purchase Agreement by and between the Company and NRM VII Holdings, Fibrocell Science approved an amendment to their Certificate of Incorporation to effect a reverse stock split of the outstanding shares of FCSC stock. Sometime prior to July 31, 2013, shareholders of the biotechnology penny stock should see a reverse split on FCSC at a ratio of anywhere from 1-for-2, 1-for-5, 1-for-10, 1-for-15, 1-for-20 or 1-for-25 to facilitate the listing on a national securities exchange.
Everything is happening according to plan since LAVIV was approved by the FDA in 2011. The $43 million dollars generated form the recent private placement and the closing of the deal which issued 232.94 million shares of FCSC stock, 35.3% of the outstanding shares, to Randal J. Kirk, NRM VII Holdings I, LLC and Intrexon Corporation, now allows for production expansion of LAVIV.
With the “baby boomer” population expanding, although its nothing more than cosmetic, LAVIV’s ability to return an aging person to a wrinkle-free smile could be a smile down the road for long investors.
About FCSC Stock
Fibrocell Science, Inc. is a cellular aesthetic and therapeutic development stage biotechnology company focused on developing novel skin and tissue rejuvenation products. The Company’s approved and clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burnscars with a patient’s own, or autologous, fibroblast cells produced in the Company’s proprietary Fibrocell Process. The Company’s lead product, LAVIV™ , is the first and only personalized aesthetic cell therapy approved by the FDA for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.
Bottom Line: FCSC is a great biotechnology penny stock to look long at. With plans of uplisting within the next 9 months and having made the changes to the capital structure needed to do such, FCSC stock could find it’s place on the “Volume Alert” lists if and when news of the uplist or any potential buy out gets leaked. You can list this one right next to FUTU and play the SEC filings.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share